Abstract: The present invention relates to a passive type low-temperature heat sources organic working fluid power generation method. The organic working fluid absorbs heat and evaporates in the first evaporator and the second in turn evaporator. When the pressure of organic working fluid reaches the set pressure, the self-operated pressure regulator valve at the outlet of the evaporator opens triggered by operating pressure. The organic working fluid vapor flows into the turbine and pushes the turbine to rotate with a high speed, driving the generator to provide output power. The low-temperature low-pressure exhaust gas flows into the condenser and condenses into liquid working fluid. Through the first and second evaporator in turn providing working steam, the turbine can maintain continuous work and provide output power. Compared with the prior technology, the present invention has reliable performance, relying on the evaporation of the working fluid in a closed space to achieve increased pressure.

Abstract: A composition is provided for modulating or attenuating the cytokine induced cell surface expression of cell adhesion molecules, comprising an antibody that binds digoxin. There is also provided a method of modulating or attenuating the cytokine induced cell surface expression of a cell adhesion molecule in a patient by administering to a digoxin antibody composition to a patient in need of such treatment.

Abstract: The invention relates to N-heterocyclic substituent-containing antibiotics, their preparation, and their use. Disclosed are sodium and potassium salts of 7-(?-((N,N?-diisopropylamidino)thio)acetylamino)-3-(((1,2,5,6-tetrahydro-2-methyl-5,6-diox o-1,2,4-triazin-3-yl)thio)methyl) cephalosporanic acid as presented by the general structure (I), their preparation, and their use. The antibiotics of the invention can be used to treat diseases caused by Gram-positive or Gram-negative bacteria such as septicaemia, gastrointestinal tract infection, and urinary tract infection. They have increased half-life in blood and lowered toxicity. They can reduce the frequency of drug use and lower medical treatment costs. They have improved stability and can be stored at ambient temperatures. The method of the invention is simple, and it produces high purity products which can meet the requirements of clinical use.

Abstract: A method for neighbor discovery including: transmitting a neighbor detection message according to a neighbor VLAN information table, where the neighbor VLAN information table includes neighbor VLAN information; receiving a neighbor response message with which a terminal responds; acquiring a MAC address of the terminal according to the neighbor response message. With the method, numerous invalid detections, heavy apparatus load and large CPU resource consumption caused by traversing a public network VLAN and a private network VLAN to conduct neighbor detection decease.

Abstract: A composition is provided for modulating or attenuating the cytokine induced cell surface expression of cell adhesion molecules, comprising an antibody that binds digoxin. There is also provided a method of modulating or attenuating the cytokine induced cell surface expression of a cell adhesion molecule in a patient by administering to a digoxin antibody composition to a patient in need of such treatment.

Abstract: Anti-infection levorotatory optically active compound (S-configuration) of prulifloxacin represented by the following formula (1) and preparation method thereof are disclosed. Said method utilizes levorotatory ulifloxacin as the raw material and the reaction is conducted in organic solvent in the presence of alkaline materials, wherein the reaction temperature is ?20° C.˜60° C. and the reaction time is 15 minutes to 24 hours.

Abstract: The present invention relates to a N-substituted matrinic acid derivative or matrine derivative, and its preparation method and uses. Specifically, the present invention relates to a compound of Formula (I) or (II) (wherein all the definitions of substituted groups are those mentioned in the specification), or a pharmaceutically acceptable salt, geometric isomer, stereoisomer, solvate, ester or prodrug thereof. The present invention further relates to a method for preparing the compound of the present invention, a pharmaceutical composition containing the compound, and uses thereof in manufacture of a medicament. The compound of the present invention can be used for prophylaxis and/or treatment of a disease or disorder associated with viral infection such as hepatitis B and/orhepatitis C and/or AIDS.

Abstract: Anti-infection levorotatory optically active compound (S-configuration) of prulifloxacin represented by the following formula (1) and preparation method thereof are disclosed. Said method utilizes levorotatory ulifloxacin as the raw material and the reaction is conducted in organic solvent in the presence of alkaline materials, wherein the reaction temperature is ?20° C.˜60° C. and the reaction time is 15 minutes to 24 hours.

Abstract: The invention relates to N-heterocyclic substituent-containing antibiotics, their preparation, and their use. Disclosed are sodium and potassium salts of 7-(?-((N,N?-diisopropylamidino)thio)acetylamino)-3-(((1,2,5,6-tetrahydro-2-methyl-5,6-dioxo-1,2,4-triazin-3-yl)thio)methyl) cephalosporanic acid as presented by the general structure (I), their preparation, and their use. The antibiotics of the invention can be used to treat diseases caused by Gram-positive or Gram-negative bacteria such as septicaemia, gastrointestinal tract infection, and urinary tract infection. They have increased half-life in blood and lowered toxicity. They can reduce the frequency of drug use and lower medical treatment costs. They have improved stability and can be stored at ambient temperatures. The method of the invention is simple, and it produces high purity products which can meet the requirements of clinical use.

Abstract: The invention discloses the pharmaceutically acceptable salts of an optically active quinolone compound useful against infection, specifically the pharmaceutically acceptable salts of (S)-6-fluoro-1-methyl-4-oxo-7-(1-piperazinyl)-1H,4H-[1,3]thiazeto[3,2-a]quinoline-3-carboxylic acid. The pharmaceutically acceptable salts of the present invention are stable and have improved water solubility. They possess higher biological activity, less toxicity for kidney and no irritation to skin and muscle.

Abstract: A set of geldanamycin derivatives and their preparation methods. Pharmaceutical compositions comprising the said compounds as an active ingredient which are used as antivirus and antitumor agents. The said derivatives are used in the manufacture of heat shock protein 90 (Hsp 90) inhibiting agents which have the utility as antivirus and antitumor agents.

Abstract: Access to system and user defined entities (objects, data items, or the like) is managed by a content manager. A privilege grants a user an ability to access system such controlled entities. An item is an atomic user data entity stored in the CM library server. A privileges table is used to store system and user defined privileges. A privilege is represented by a row in the table. Each privilege has a unique privilege code, with codes 0 to 999 reserved to store system-defined privileges and codes beyond 999 open for user-defined privileges thus allowing application specific privileges to be added without limit.

Abstract: A method of controlling access in a content management system includes defining a domain among a plurality of domains for the content management system and designating a domain administrator for the domain. This enables the domain administrator to perform administrative tasks within the domain without revealing or affecting information in other domains of the content management system. For example, a domain administrator can view user information only for users associated with that domain. The domain administrator also can associate a user with only the defined domain, thereby limiting the user's access to information in the system to information associated with the domain.

Abstract: This invention relates generally to the field of glycated protein detection. In particular, the invention provides chimeric proteins, nucleic acids encoding the chimeric proteins, methods and kits for assaying for a glycated protein in a sample, using inter alia, an amadoriase.

Abstract: System and method for authorizing access to an entity by a user, by binding an access control list to each entity; specifying for the user a set of user privileges; intersecting the access control list and set of user privileges in a compiled ACL table; incrementally refreshing the compiled ACL table responsive to run time modification of relevant tables containing the access control list and set of user privileges; and referencing the compiled access control list to authorize a user request to access an entity.

Abstract: A system and method for authorizing access to a controlled entity by a user. A set of user privileges is provided for user; and a content manager intersects an access control list (ACL) and the set of user privileges to authorize access. Binding level control indicia selectively binds an access control list (ACL) to the controlled entity at item type, item, mixed, or library binding level. An item type comprises one or more component items with each component item having one or more item views which together form an item type view. A content manager is responsive to the binding level to perform ACL checking for authorizing access to the controlled entity by the user.

Abstract: This invention relates generally to the field of glycated protein detection. In particular, the invention provides chimeric proteins, nucleic acids encoding the chimeric proteins, methods and kits for assaying for a glycated protein in a sample, using inter alia, an amadoriase.

Abstract: Access to system and user defined entities (objects, data items, or the like) is managed by a content manager. A privilege grants a user an ability to access system such controlled entities. An item is an atomic user data entity stored in the CM library server. A privileges table is used to store system and user defined privileges. A privilege is represented by a row in the table. Each privilege has a unique privilege code, with codes 0 to 999 reserved to store system-defined privileges and codes beyond 999 open for user-defined privileges thus allowing application specific privileges to be added without limit.

Abstract: Access to system and user defined entities (objects, data items, or the like) is managed by a content manager. A privilege grants a user an ability to access system such controlled entities. An item is an atomic user data entity stored in the CM library server. A privileges table is used to store system and user defined privileges. A privilege is represented by a row in the table. Each privilege has a unique privilege code, with codes 0 to 999 reserved to store system-defined privileges and codes beyond 999 open for user-defined privileges thus allowing application specific privileges to be added without limit.

Abstract: This invention relates generally to the field of glycated protein detection. In particular, the invention provides chimeric proteins, nucleic acids encoding the chimeric proteins, methods and kits for assaying for a glycated protein in a sample, using inter alia, an amadoriase.